A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
- PMID: 33176636
- DOI: 10.2174/0929867327666201111142307
A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Abstract
Nuclear Factor-κappa B (NF-κB) is a family of critical transcription factors of the inflammatory pathway and plays an imperative role in the progression of various cancers such as breast, lung, liver, pancreatic, prostate and multiple types of lymphoma. NF- κB develops an inherent relationship between inflammation and cancer. It is a crucial factor that controls the ability of malignant and pre-neoplastic cells to prevent programmed cell death-based tumor-surveillance channels. Due to its high significance in the onset and progression of various cancers, it has become an excellent target for cancer therapy. The emerging targeted therapies provide a lot of hope, whereby a single protein or generally the target enzyme is completely blocked. Several natural compounds have shown anticancer and anti-inflammatory activities by inhibiting the NF-κB pathway in various cancer types. About 750 natural and synthetic inhibitors of the NF-κB have been reported. These inhibitors include microbial and viral proteins, small RNA/DNA, antioxidants, small molecules, peptides, and engineered constitutively active polypeptides, all of which may inhibit canonical and alternative NF-κB pathways. Thus, blocking or targeting the NF-κB-signaling pathways using natural and synthetic compounds could be a potential mechanism to cure the NF-κB induced tumors.
Keywords: Cancer; IKKβ.; Inhibitors; NEMO; NF-κB; NIK.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Inhibitors of NF-kappaB signaling: 785 and counting.Oncogene. 2006 Oct 30;25(51):6887-99. doi: 10.1038/sj.onc.1209982. Oncogene. 2006. PMID: 17072334 Review.
-
Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A.BMC Genomics. 2010 Dec 2;11 Suppl 4(Suppl 4):S25. doi: 10.1186/1471-2164-11-S4-S25. BMC Genomics. 2010. PMID: 21143809 Free PMC article.
-
Novel non-peptide small molecules preventing IKKβ/NEMO association inhibit NF-κB activation in LPS-stimulated J774 macrophages.Biochem Pharmacol. 2016 Mar 15;104:83-94. doi: 10.1016/j.bcp.2016.01.008. Epub 2016 Jan 14. Biochem Pharmacol. 2016. PMID: 26776306
-
Engineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancer.Biomed Pharmacother. 2022 Dec;156:113932. doi: 10.1016/j.biopha.2022.113932. Epub 2022 Nov 3. Biomed Pharmacother. 2022. PMID: 36411621 Review.
-
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.Oncogene. 2014 Feb 27;33(9):1135-47. doi: 10.1038/onc.2013.49. Epub 2013 Mar 4. Oncogene. 2014. PMID: 23455325 Free PMC article.
Cited by
-
Phosphorylation of RelA/p65 Ser536 inhibits the progression and metastasis of hepatocellular carcinoma by mediating cytoplasmic retention of NF-κB p65.Gastroenterol Rep (Oxf). 2024 Nov 4;12:goae094. doi: 10.1093/gastro/goae094. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 39498383 Free PMC article.
-
Expression and clinical significance of CLDN7 and its immune-related cells in breast cancer.Diagn Pathol. 2024 Aug 22;19(1):113. doi: 10.1186/s13000-024-01513-1. Diagn Pathol. 2024. PMID: 39175074 Free PMC article.
-
Yin Yang 1-stimulated long noncoding RNA bladder cancer-associated transcript 1 upregulation facilitates esophageal carcinoma progression via the microRNA-5590-3p/programmed cell death-ligand 1 pathway.Bioengineered. 2022 Apr;13(4):10244-10257. doi: 10.1080/21655979.2022.2061303. Bioengineered. 2022. PMID: 35435118 Free PMC article.
-
Targeting PI3K/Akt/mTOR Pathway by Different Flavonoids: A Cancer Chemopreventive Approach.Int J Mol Sci. 2021 Nov 18;22(22):12455. doi: 10.3390/ijms222212455. Int J Mol Sci. 2021. PMID: 34830339 Free PMC article. Review.
-
Effects of curcumin and ursolic acid in prostate cancer: A systematic review.Urologia. 2024 Feb;91(1):90-106. doi: 10.1177/03915603231202304. Epub 2023 Sep 30. Urologia. 2024. PMID: 37776274 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous